Related Experiment Video

Updated: Jul 15, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
10:26

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential

Michael B Chancellor1, Fernando de Miguel

  • 1Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Geriatrics
|May 11, 2007
PubMed

Insights

Overactive bladder (OAB) treatments can interact with other medications. Trospium, unlike other OAB drugs, is not metabolized by CYP450 enzymes, suggesting a lower risk of drug interactions for older adults.

Area of Science:

  • Pharmacology
  • Geriatrics

Background:

  • Overactive bladder (OAB) significantly impacts the quality of life for the elderly.
  • Anticholinergic medications are the primary treatment for OAB.
  • Polypharmacy in older adults increases the risk of adverse drug events and interactions.

Purpose of the Study:

  • To evaluate the potential for drug-drug interactions among OAB medications.
  • To identify OAB treatments that may be safer for elderly patients with polypharmacy.

Main Methods:

  • Review of OAB drug metabolism pathways, focusing on cytochrome P450 (CYP450) enzyme involvement.
  • Comparison of the metabolic profiles of tolterodine, darifenacin, solifenacin, oxybutynin, and trospium.

Main Results:

  • Tolterodine, darifenacin, solifenacin, and oxybutynin are extensively metabolized by CYP450 enzymes.
  • Trospium is eliminated unchanged and is not metabolized by CYP450 enzymes.

Conclusions:

  • Trospium's lack of CYP450 metabolism suggests a lower potential for drug-drug interactions.
  • Trospium may be a safer OAB treatment option for older adults managing multiple medications.

Related Concept Videos

Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Cholinergic Antagonists: Pharmacokinetics01:24

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations,  while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...